Sensei Biotherapeutics, Inc. (SNSE): Price and Financial Metrics


Sensei Biotherapeutics, Inc. (SNSE): $1.81

0.11 (+6.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SNSE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SNSE Stock Price Chart Interactive Chart >

Price chart for SNSE

SNSE Price/Volume Stats

Current price $1.81 52-week high $13.00
Prev. close $1.70 52-week low $1.45
Day low $1.70 Volume 48,400
Day high $1.85 Avg. volume 83,496
50-day MA $1.92 Dividend yield N/A
200-day MA $5.74 Market Cap 55.44M

Sensei Biotherapeutics, Inc. (SNSE) Company Bio


Sensei Biotherapeutics, Inc. operates as a clinical-stage immunotherapy company. The Company focuses in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Sensei Biotherapeutics serves customers in the United States.


SNSE Latest News Stream


Event/Time News Detail
Loading, please wait...

SNSE Latest Social Stream


Loading social stream, please wait...

View Full SNSE Social Stream

Latest SNSE News From Around the Web

Below are the latest news stories about Sensei Biotherapeutics Inc that investors may wish to consider to help them evaluate SNSE as an investment opportunity.

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) insiders placed bullish bets worth US$1.0m in the last 12 months

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | January 17, 2022

Sensei Biotherapeutics names Erin Colgan as CFO

No summary available.

Seeking Alpha | January 6, 2022

Sensei Biotherapeutics Announces Executive Promotions

Company names Erin Colgan as chief financial officer and Robert Pierce, M.D. as chief R&D officerBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced two key promotions within the company’s senior management team. Erin Colgan, formerly senior vice president of finance and administration, has been appointed to chief financial officer. Robe

Yahoo | January 6, 2022

Sensei Biotherapeutics Named a Winner of Comparablys Best CEO Award

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 Best CEOs.

Intrado Digital Media | December 16, 2021

Sensei Biotherapeutics Named a Winner of Comparably’s Best CEO Award

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has won a Comparably award for 2021 “Best CEOs.” “What makes Comparably awards so meaningful is that they are based exclusively on employee feedback,” said Elisabeth Colunio, Vice President of Human Resources. “We are thrilled but not surprised to see John recognized as a 2021 B

Yahoo | December 16, 2021

Read More 'SNSE' Stories Here

SNSE Price Returns

1-mo 16.77%
3-mo -49.86%
6-mo -73.69%
1-year -85.44%
3-year N/A
5-year N/A
YTD -68.79%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.655 seconds.